GlaxoSmithKline to Start Testing Ebola Vaccine

A clinical trial for GlaxoSmithKline‘s (GSK) Ebola vaccine is set to begin soon.

Ebola Vaccine

The announcement comes during the worst outbreak of Ebola recorder with the virus killing close to 1,000 people in West Africa. The Ebola vaccine trial is waiting for approval from the U.S. Food and Drug Administrationg to Phase I testing in humans.

GlaxoSmithKline’s drug has already shown plenty of promise in its animal studies with primates. The clinical trial could begin as early as fall 2014.

Ebola has no proven cure or vaccine to prevent infection. The World Health Organisation has declared the outbreak an international health emergency.

GSK stock is flat Monday afternoon.

More Health News:

Article printed from InvestorPlace Media,

©2021 InvestorPlace Media, LLC